Meta-analysis of Haikun Shenxi Capsule in the Treatment of Chronic Renal Failure / 中国药房
China Pharmacy
; (12): 3801-3804, 2017.
Article
em Zh
| WPRIM
| ID: wpr-662954
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE:
To systematically review therapeutic efficacy of Haikun shenxi capsule in the treatment of chronic renal failure (CRF).METHODS:
Retrieved from Central,PubMed,EMBase,CJFD,CBM,VIP and Wanfang database,randomized clinical trials (RCTs) about Haikun shenxi capsule combined with routine treatment (trial group)vs.single routine treatment (control group) in the treatment of CRF were collected.Meta-analysis was performed by Rev Man 5.3 software after screening literature,extracting data and evaluating quality by using risk bias evaluation of Cochrane collaboration network.RESULTS:
A total of 10 RCTs were included eventually,involving 704 patients.The results of analysis showed that compared to general therapy,Haikun shenxi capsule could improve total effective rate [RR =4.42,95 % CI (2.70,7.22),P< 0.001],and could reduce SCr[MD =-140.37,95 % CI (-191.72,-89.03),P< 0.001],BUN[MD =-5.49,95 % CI (-8.36,-2.63),P< 0.001] and 24 h-Upro [MD =-0.43,95 % CI (-0.62,-0.23),P< 0.001],with statistical significance.CONCLUSIONS:
The clinical efficacy of Haikun shenxi capsule in the treatment of CRF is good and significantly improve related indexes of renal function.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Idioma:
Zh
Revista:
China Pharmacy
Ano de publicação:
2017
Tipo de documento:
Article